pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,386 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints892BioPharma Dive344BioSpace307Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7601Rare Disease1873Cardiology1743Immunology1478Hematology1321Vaccines1197Pulmonology
  • NIH scientist and fellow charged with smuggling deactivated mpox virus into U.S.
    Two researchers at a U.S. government laboratory have been indicted for attempting to bring vials of deactivated mpox virus into the United States without proper authorization. The charges involve V…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Pope’s AI Encyclical Offers Guidance for Catholic Hospitals and Health Care
    The article notes that Pope Francis released an encyclical addressing artificial intelligence and examines what that means for Catholic hospitals and the broader health‑care system. STAT’s AI Prog…
    STAT · 3mo agoNeutral↗ source
← prev
page 72 of 96
next →
fda recalls70
fda medwatch60
fda press38
1186
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism474
Infectious Disease444
  • Legend surges on early data for ‘in vivo’ lymphoma cell therapy
    Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Concerns arise that military practices may contribute to eating disorders amid broader health updates
    The Morning Rounds newsletter, written by Theresa Gaffney, raises a question about whether military environments are encouraging eating disorders. The piece is part of a daily health briefing that…
    STAT · 3mo agoNeutral↗ source
  • Researchers urge sweeping policy action on ultra-processed foods after poll shows bipartisan concern
    A special edition of the American Journal of Public Health brings together leading researchers on ultra-processed foods and delivers a clear message to policymakers: take action now. Food policy s…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Rising AI battle between hospitals and insurers drives soaring medical bills, says pediatric cardiologist
    Darshak Sanghavi, a pediatric cardiologist and chief medical officer of Machinify, writes an opinion piece about an emerging AI conflict between health providers and insurers over patient records a…
    STAT · 3mo agoNegative↗ source
  • Military culture may increase risk of eating disorders among men, expert warns
    Paula Chesley, a yoga and meditation instructor who works with people with eating disorders, notes that male clients are rare but many have served in the military. She says that, based on her expe…
    STAT · 3mo agoNegative↗ source
  • Public health must address the rapidly growing Amish population, experts say
    The STAT First Opinion podcast highlighted that the Amish community is expanding quickly, roughly doubling every two decades, which will increasingly affect public health planning. Researchers Bra…
    STAT · 3mo agoNeutral↗ source
  • Fulcrum Therapeutics considers sale after FDA blocks sickle cell drug development
    Fulcrum Therapeutics announced it is undertaking a strategic review that could lead to a sale after its lead sickle cell candidate, pociredir, was effectively blocked by the FDA. The agency cited…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • AbiVax shares plunge as safety concerns shadow strong ulcerative colitis trial results
    AbiVax reported Phase 3 data for its experimental therapy obefazimod in patients with moderately to severely active ulcerative colitis. Two dose levels achieved placebo‑adjusted clinical remission…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • ASCO 2026 Highlights Bispecific Antibodies, ADCs and New Advances in RAS-Targeted and Prostate Cancer Therapies
    The meeting featured a lively comparison of bispecific antibodies and antibody-drug conjugates as leading modalities in oncology. Researchers presented data suggesting that targeting mutant RAS pr…
    BioPharma Dive · 3mo agoPositive↗ source
  • Celcuity's gedatolisib trial cuts death risk but misses investor expectations
    Celcuity reported data from its Phase 3 VIKTORIA-1 trial evaluating gedatolisib in HR‑positive, HER2‑negative breast cancer with PIK3CA mutations. The trial enrolled 350 patients who had progresse…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Eli Lilly gives 340B hospitals a week to share data or lose drug discounts
    Eli Lilly has told hospitals and medical groups that participate in the 340B drug discount program that they must submit claims data for all Lilly medications by the coming Monday, or they will be…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • Longevity startup NewLimit secures $435 million Series C as it prepares first liver drug trial
    NewLimit, a longevity‑focused biotech founded in 2021, announced a Series C financing that brought in $435 million, pushing its valuation to about $3.1 billion. The round was led by Founders Fund…
    STAT · 3mo agoDealPositive↗ source
  • Radiopharmaceutical shows promise after Pluvicto; Vera Therapeutics gains FDA agreement to speed IgA nephropathy data analysis
    A new radiopharmaceutical is generating interest for use after patients have completed Pluvicto therapy, suggesting a potential follow‑on treatment option. Abivax reported encouraging results from…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Eli Lilly warns 340B hospitals to submit claims data within five days or lose price discounts
    Eli Lilly has given roughly 50 hospitals that participate in the federal 340B drug discount program a five‑day deadline to provide comprehensive claims data. The company says that if the data are n…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Trump administration releases Medicaid work-requirement rules, prompting state compliance challenges
    The Morning Rounds newsletter highlighted several health‑policy developments, notably new Medicaid work‑requirement rules and fast‑tracked funding for experimental Ebola vaccines. The Trump admini…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • US-made packaging equipment offers faster lead times and regulatory alignment for pharma manufacturers
    As pharma firms upgrade their packaging lines, the source of the equipment is becoming a strategic factor rather than a simple purchasing decision. Domestic production shortens lead times and redu…
    BioPharma Dive · 3mo agoPositive↗ source
  • States tighten rules on corporate telehealth, targeting business structures behind direct-to-consumer care
    Telehealth has grown into a multibillion‑dollar industry, with brands like Hims & Hers and Teladoc becoming widely recognized. Despite their visibility, many patients are unaware that corporate te…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Telemedicine surge could eliminate traditional doctor’s office waiting rooms
    Emergency physician Iyesatta Massaquoi Emeli reflects on how the concept of waiting has been built into medical practice, from the lobby to the triage process, shaping patients' experience of care.…
    STAT · 3mo agoPositive↗ source
  • Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B deal
    Servier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Medicare launches $50/month coverage for Wegovy and Zepbound but withholds cost to taxpayers
    Medicare announced a temporary “GLP-1 Bridge” program that will allow adults 65 and older to receive the obesity treatments Wegovy and Zepbound for $50 a month beginning July 1. The program runs t…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis pill shows high remission rates but cancer cases spark safety worries
    Abivax reported that its experimental oral therapy for ulcerative colitis achieved strong efficacy in a Phase 3 maintenance trial involving 580 patients who had previously responded in shorter stud…
    STAT · 3mo agoNegative readoutNegative↗ source
  • ASCO Highlights Barriers to Cancer Care and New Treatments Amid Memorable Pancreatic Cancer Study Ovation
    The annual ASCO meeting featured extensive discussion of the obstacles patients face in accessing cancer care and showcased a range of emerging therapies. STAT compiled a quick‑take newsletter tha…
    STAT · 3mo agoNeutral↗ source
  • Revolution Medicines reports pancreatic cancer drug daraxonrasib extends median survival to 13.2 months in second-line study
    Revolution Medicines released detailed data confirming that its experimental pancreatic cancer therapy, daraxonrasib, improved overall survival for patients with advanced disease. In the second‑lin…
    STAT · 3mo agoPositive readoutPositive↗ source